Brokerages Set $8.25 Target Price for AzurRx BioPharma Inc (AZRX)
AzurRx BioPharma Inc (NASDAQ:AZRX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $8.25 for the company and are forecasting that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 158 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Friday, November 17th.
Shares of AzurRx BioPharma (NASDAQ AZRX) traded up $0.02 during trading hours on Friday, reaching $3.71. The company had a trading volume of 36,100 shares, compared to its average volume of 60,367. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.
TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/brokerages-set-8-25-target-price-for-azurrx-biopharma-inc-azrx.html.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.